Prometheus Biosciences Inc Revenue Growth Rates (RXDX), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Prometheus Biosciences Inc   (NASDAQ: RXDX)
 

RXDX's Revenue Growth by Quarter and Year

Prometheus Biosciences Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

RXDX Revenue (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
4th Quarter June -
3rd Quarter March 1.11
2nd Quarter December 0.65
1st Quarter September 0.97
FY 2.72

RXDXs Annual Revenue
Prometheus Biosciences Inc 's Revenue in the fiscal year 2022 $ 6.81 millions
Prometheus Biosciences Inc 's Revenue in the fiscal year 2021 $ 3.13 millions
Prometheus Biosciences Inc 's Revenue in the fiscal year 2016 $ 0.00 millions
Prometheus Biosciences Inc 's Revenue in the fiscal year 2015 $ 0.00 millions
Prometheus Biosciences Inc 's Revenue in the fiscal year 2014 $ 0.15 millions




RXDX Revenue third quarter 2023 Y/Y Growth Comment
Prometheus Biosciences Inc reported drop in Revenue in the third quarter 2023 by -71.81% to $ 1.11 millions, from the same quarter in 2022.
The fall in the third quarter 2023 Prometheus Biosciences Inc 's Revenue compares unfavorably to the Company's average Revenue doubling of 661.54%.

Looking into third quarter 2023 results within Major Pharmaceutical Preparations industry 230 other companies have achieved higher Revenue growth. While Prometheus Biosciences Inc ' s Revenue meltdown of -71.81% ranks overall at the positon no. 4009 in the third quarter 2023.


RXDX Revenue ( Y/Y Growth %) 2023
 2022 2021 2020
4th Quarter June - 284.85 % 83.33 % -
3rd Quarter March -71.81 % 415.79 % 230.43 % -
2nd Quarter December -37.5 % 126.09 % - -
1st Quarter September -3.96 % 180.56 % - -
FY   - 279.06 % 365.85 % -

Financial Statements
Prometheus Biosciences Inc 's third quarter 2023 Revenue $ 1.11 millions RXDX's Income Statement
Prometheus Biosciences Inc 's third quarter 2022 Revenue $ 3.92 millions Quarterly RXDX's Income Statement


RXDX Revenue (Quarter on Quarter Growth %)

 2023
 2022 2021 2020
4th Quarter June - -67.6 % -56.58 % -21.74 %
3rd Quarter March 70 % 276.92 % 65.22 % -
2nd Quarter December -32.99 % 2.97 % 27.78 % -
1st Quarter September -23.62 % 206.06 % 100 % -
FY (Year on Year)   - 279.06 % 365.85 % -


Back to RXDX Growth rate Comparisons >> Back to RXDX Growth rate Comparisons >>


Revenue third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #231
Healthcare Sector #621
Overall #4009

Revenue Y/Y Growth Statistics
High Average Low
4900 % 661.54 % -100 %
(Jun 30 2014)   (Jun 30 2015)
Revenue third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #231
Healthcare Sector #621
Overall #4009
Revenue Y/Y Growth Statistics
High Average Low
4900 % 661.54 % -100 %
(Jun 30 2014)   (Jun 30 2015)

Revenue by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Prometheus Biosciences Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
277.92 % 16.17 % -100 %
(Mar 31 2022)  


RXDX's III. Quarter Q/Q Revenue Comment
Prometheus Biosciences Inc achieved in the III. Quarter 2023 above company average sequential Revenue jump of 70%, to $ 1.11 millions, from $0.65 millions in the second quarter.

Within Major Pharmaceutical Preparations industry 30 other companies have achieved higher Revenue quarter on quarter growth. While Prometheus Biosciences Inc 's Revenue growth quarter on quarter, overall rank is 223.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #31
Healthcare Sector #63
Overall #223
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #31
Healthcare Sector #63
Overall #223
Revenue Q/Q Growth Statistics
High Average Low
277.92 % 16.17 % -100 %
(Mar 31 2022)  


RXDX's III. Quarter Q/Q Revenue Comment
Prometheus Biosciences Inc achieved in the III. Quarter 2023 above company average sequential Revenue jump of 70%, to $ 1.11 millions, from $0.65 millions in the second quarter.

Within Major Pharmaceutical Preparations industry 30 other companies have achieved higher Revenue quarter on quarter growth. While Prometheus Biosciences Inc 's Revenue growth quarter on quarter, overall rank is 223.


Prometheus Biosciences Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Mar 31 2023)		 12 Months Ending
(Dec 31 2022)		 12 Months Ending
(Sep 30 2022)		 12 Months Ending
(Jun 30 2022)		 12 Months Ending
(Mar 31 2022)
Cumulative Revenue 12 Months Ending $ 4.00 $ 6.81 $ 7.19 $ 7.23 $ 6.29
Y / Y Revenue Growth (TTM) -36.47 % 117.61 % 181.53 % 278.98 % 257.07 %
Year on Year Revenue Growth Overall Ranking # 258 # 85 # 0 # 0 # 0
Seqeuential Revenue Change (TTM) -41.33 % -5.34 % -0.53 % 15 % 100.96 %
Seq. Revenue Growth (TTM) Overall Ranking # 291 # 107 # 2468 # 339 # 292


Cumulative Revenue growth Comment
For the 12 months ended Mar 31 2023 Prometheus Biosciences Inc reported a drop in Revenue by -36.47% year on year, to $4 millions, compare to the 117.61% growth at Dec 31 2022.

In the Healthcare sector 70 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 85 to 258.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 39
Healthcare Sector # 71
Overall # 258

Revenue TTM Y/Y Growth Statistics
High Average Low
117.61 %
 40.57 %
-36.47 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 39
Sector # 79
S&P 500 # 291
Cumulative Revenue growth Comment
For the 12 months ended Mar 31 2023 Prometheus Biosciences Inc reported a drop in Revenue by -36.47% year on year, to $4 millions, compare to the 117.61% growth at Dec 31 2022.

In the Healthcare sector 70 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 85 to 258.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 39
Healthcare Sector # 71
Overall # 258

Revenue TTM Y/Y Growth Statistics
High Average Low
117.61 %
40.57 %
-36.47 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 39
Sector # 79
S&P 500 # 291




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
RXDX's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue drop for the quarter ending Mar 31 2023 within Healthcare SectorY/Y Change %Revenue for the quarter ending Mar 31 2023
Regenerx Biopharmaceuticals inc -0.01%$ -0.005 millions
Community Health Systems Inc -0.10%$ -0.096 millions
West Pharmaceutical Services Inc -0.47%$ -0.472 millions
Butterfly Network Inc -0.63%$ -0.629 millions
Qhslab Inc -0.71%$ -0.712 millions
Waters Corporation-0.85%$ -0.854 millions
Dariohealth Corp -0.86%$ -0.856 millions
Fresenius Medical Care Ag-1.06%$ -1.058 millions
Acorda Therapeutics Inc -1.22%$ -1.225 millions
Baxter International Inc -1.56%$ -1.565 millions
Kymera Therapeutics Inc -1.62%$ -1.621 millions
Nature s Sunshine Products inc -1.68%$ -1.683 millions
Organon and Co -1.85%$ -1.851 millions
Scientific Industries Inc -2.08%$ -2.077 millions
Amgen Inc -2.13%$ -2.132 millions
Healthcare Services Group Inc -2.24%$ -2.245 millions
Adaptive Biotechnologies Corporation-2.52%$ -2.519 millions
Bristol myers Squibb Company-2.67%$ -2.670 millions
Caredx Inc -2.71%$ -2.712 millions
Biogen Inc -2.72%$ -2.717 millions
Innovage Holding Corp -2.72%$ -2.718 millions
Cardiff Lexington Corporation-2.73%$ -2.727 millions
Apyx Medical Corp-2.81%$ -2.810 millions
Avanos Medical Inc -2.89%$ -2.888 millions
Align Technology inc -3.09%$ -3.090 millions
Bio rad Laboratories Inc -3.32%$ -3.317 millions
Enhabit Inc -3.35%$ -3.354 millions
National Healthcare Corp-3.38%$ -3.377 millions
Thermogenesis Holdings Inc -3.42%$ -3.417 millions
Mesoblast Limited-3.58%$ -3.580 millions


About Prometheus Biosciences Inc Revenue Growth Rates (RXDX), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: the company’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.